0307 GMT - Sigma Healthcare's elevated profile from its impending merger with Chemist Warehouse and its likely inclusion as one of Australia's 100 largest listed companies earn the pharmaceutical supplier a new bull at Morgans. Analyst Scott Power raises his recommendation on the stock to add from hold, telling investors that Sigma will attract significant passive buying from funds if, as he expects, it is included in Australia's S&P/ASX 100 and other global indexes. He adds a 30% liquidity premium to his valuation as a result. Target price rises 35% to A$2.98. Shares are up 0.4% at A$2.68. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 22:07 ET (03:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。